Does Ezetimibe Harm Liver Function?
Ezetimibe, a cholesterol absorption inhibitor used to lower LDL cholesterol, shows minimal impact on liver function in most patients. Clinical trials and post-marketing data report low rates of elevated liver enzymes (ALT/AST). In monotherapy trials, ALT elevations >3x upper limit of normal (ULN) occurred in 0.5-2% of patients, compared to 0-1.6% on placebo.[1][2] Combination with statins raises this slightly to 1-3%, but rarely leads to discontinuation or serious injury.[3]
How Does It Compare to Statins on the Liver?
Unlike statins, which inhibit HMG-CoA reductase in the liver and can cause transaminase elevations in 0.5-3% of users (dose-dependent), ezetimibe acts in the intestine. It blocks NPC1L1 protein to reduce dietary cholesterol uptake, sparing direct liver stress. Dual therapy (ezetimibe + statin) does not amplify liver risks beyond statin monotherapy levels in large outcomes trials like IMPROVE-IT, where ALT/AST >3x ULN was ~2.5% over 7 years.[4][5]
What Do Liver Enzyme Changes Look Like in Practice?
Monitoring shows:
- Mild, transient ALT/AST rises (1-3x ULN) in <2% of patients, often resolving without intervention.
- Severe elevations (>10x ULN) or jaundice in <0.1%, with few confirmed drug-induced liver injury (DILI) cases linked to ezetimibe alone.[6]
FDA label recommends baseline and periodic LFTs, especially with statins, but no routine testing for ezetimibe monotherapy.[2]
Are There Risks for Patients with Liver Disease?
Avoid in active liver disease or unexplained persistent transaminase elevations. Use caution in moderate-severe hepatic impairment (Child-Pugh B/C), as exposure increases 3-4x due to reduced metabolism, though no dose adjustment is needed.[2][7] No increased hepatotoxicity observed in cirrhosis studies. Rare case reports link ezetimibe-statin combos to autoimmune-like hepatitis, but causality is unclear.[8]
What Happens If Liver Enzymes Rise?
Most elevations are asymptomatic and reverse upon stopping the drug. Clinical guidelines (AASLD) classify ezetimibe as low DILI risk (R ratio <2 in Hy's law cases).[6] Rechallenge is generally safe if mild. Patients with NAFLD may see no worsening; some small studies note stable or improved liver fat with ezetimibe.[9]
[1] Zetia (ezetimibe) Prescribing Information, Merck
[2] FDA Label for Ezetimibe
[3] Cannon CP et al., N Engl J Med 2015; IMPROVE-IT trial
[4] Baigent C et al., Lancet 2010; Cholesterol Treatment Trialists meta-analysis
[5] Drugs.com Ezetimibe Side Effects
[6] Chalasani N et al., Hepatology 2021; AASLD DILI guidelines
[7] Zhu Y et al., Clin Pharmacokinet 2002; pharmacokinetics in hepatic impairment
[8] LiverTox: Ezetimibe, NIH
[9] Lee J et al., J Lipid Res 2019; NAFLD substudy